tetano
Editor, Senior Moderator
Ocul Immunol Inflamm
. 2022 Feb 28;1-5.
doi: 10.1080/09273948.2022.2042325. Online ahead of print.
Bilateral Panuveitis with Occlusive Vasculitis following Coronavirus Disease 2019 Vaccination
Mélanie Hébert[SUP] 1 [/SUP], Simon Couture[SUP] 1 [/SUP], Isabelle Schmit[SUP] 1 [/SUP]
Affiliations
Abstract
Purpose: To report a case of bilateral panuveitis and occlusive vasculitis following COVID-19 vaccination.
Study design: Case report.
Results: A 41-year-old otherwise healthy male presented with progressive vision loss and floaters starting 48 hours after a first dose of COVID-19 vaccine. Examination initially showed bilateral anterior uveitis, but this evolved into bilateral panuveitis with occlusive vasculitis despite topical corticosteroids over two weeks. The patient underwent extensive testing for other etiologies which were excluded. He was successfully treated with a gradual taper of topical and systemic corticosteroids leading to improvement of signs and symptoms. Follow-up is maintained for observation of avascular zones with possible neovascularization which could require laser as needed.
Conclusions: The temporal association between vaccine and presentation makes this a plausible etiology. This remains a rare adverse event, but clinicians should be aware of this possibility to include it in their differential diagnosis when confronted with idiosyncratic ocular presentations.
Keywords: Coronavirus disease 2019; SARS-CoV-2; autoimmunity; inflammation; mRNA vaccine; panuveitis; retinal vasculitis; vaccination.
. 2022 Feb 28;1-5.
doi: 10.1080/09273948.2022.2042325. Online ahead of print.
Bilateral Panuveitis with Occlusive Vasculitis following Coronavirus Disease 2019 Vaccination
Mélanie Hébert[SUP] 1 [/SUP], Simon Couture[SUP] 1 [/SUP], Isabelle Schmit[SUP] 1 [/SUP]
Affiliations
- PMID: 35226580
- DOI: 10.1080/09273948.2022.2042325
Abstract
Purpose: To report a case of bilateral panuveitis and occlusive vasculitis following COVID-19 vaccination.
Study design: Case report.
Results: A 41-year-old otherwise healthy male presented with progressive vision loss and floaters starting 48 hours after a first dose of COVID-19 vaccine. Examination initially showed bilateral anterior uveitis, but this evolved into bilateral panuveitis with occlusive vasculitis despite topical corticosteroids over two weeks. The patient underwent extensive testing for other etiologies which were excluded. He was successfully treated with a gradual taper of topical and systemic corticosteroids leading to improvement of signs and symptoms. Follow-up is maintained for observation of avascular zones with possible neovascularization which could require laser as needed.
Conclusions: The temporal association between vaccine and presentation makes this a plausible etiology. This remains a rare adverse event, but clinicians should be aware of this possibility to include it in their differential diagnosis when confronted with idiosyncratic ocular presentations.
Keywords: Coronavirus disease 2019; SARS-CoV-2; autoimmunity; inflammation; mRNA vaccine; panuveitis; retinal vasculitis; vaccination.